Tradipitant, sold under the brand name Nereus, is a medication used as prevention of vomiting induced by motion (motion sickness). It is a neurokinin 1 receptor antagonist. It works by blocking substance P, a small signaling molecule. VLY-686 was purchased by Vanda Pharmaceuticals from Eli Lilly and Company in 2012. Tradipitant was approved for medical use in the United States in December 2025.
Medical uses Tradipitant is indicated for the prevention of vomiting induced by motion.
Society and culture
Legal status Tradipitant was approved for medical use in the United States in December 2025.
Names Tradipitant is the international nonproprietary name. Tradipitant is sold under the brand name Nereus.
References
External links "Tradipitant ( Code - C152707 )". EVS Explore. Clinical trial number NCT04327661 for "Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness" at ClinicalTrials.gov Clinical trial number NCT05903924 for "Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness" at ClinicalTrials.gov


